Shane Paul Dormady, MD
Hematology/Oncology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 35
- 9 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
35 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dormady’s office at (408) 866-4070 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
35 of 35 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A87232 · Current
Licensed to practise in California · since 2004 · expires 2027-10-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$392,552
Medicare paid this office $392,552 for 805 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 651 | $232,648 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $68,923 | $106 |
| Telephone medical discussion with physician, 21-30 minutes | 227 | $50,034 | $119 |
| New patient visit (60+ min) | 137 | $22,175 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $10,475 | $148 |
See all 7 services
| Long return visit (40+ min) | 651 | $232,648 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 98 | $68,923 | $106 |
| Telephone medical discussion with physician, 21-30 minutes | 227 | $50,034 | $119 |
| New patient visit (60+ min) | 137 | $22,175 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $10,475 | $148 |
| Long return visit (40+ min) | 19 | $2,819 | $128 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,885 | $105 |
Who their Medicare patients are
805 Original Medicare patients in 2024. Average age 78 · Under 65 1% · 85 and older 22% · Women 53% · Also on Medicaid 9% · Health risk score 1.57. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 70% · Cancer 58% · Coronary heart disease 28% · Diabetes 25% · Chronic kidney disease 22% · Atrial fibrillation 21% · Heart failure 16% · Depression 15% · COPD 10% · Stroke 10% · Dementia 8%.
The office billed $1,862,460, Medicare allowed $520,544 and paid $392,552; for 3,261 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 805 | 3,261 | 78 | 1.57 | $1,862,460 | $392,552 |
| 2023 | 742 | 2,751 | 77 | 1.59 | $1,612,774 | $328,551 |
| 2022 | 679 | 2,434 | 77 | 1.52 | $1,469,445 | $296,379 |
| 2021 | 651 | 2,743 | 77 | 1.65 | $1,457,845 | $327,722 |
| 2020 | 635 | 2,740 | 77 | 1.85 | $1,158,261 | $234,397 |
| 2019 | 661 | 3,095 | 77 | 1.84 | $1,299,108 | $275,333 |
| 2018 | 515 | 1,508 | 77 | 1.71 | $649,838 | $157,946 |
| 2017 | 709 | 2,611 | 77 | 1.75 | $1,031,358 | $299,773 |
| 2016 | 831 | 4,121 | 77 | 1.80 | $1,260,217 | $375,506 |
| 2015 | 890 | 4,709 | 77 | 1.86 | $1,366,480 | $404,163 |
| 2014 | 927 | 5,210 | 77 | 1.77 | $1,515,106 | $347,899 |
| 2013 | 829 | 4,582 | 77 | 1.82 | $970,061 | $357,780 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Long return visit (40+ min) | 617 | $215,964 | $121 |
| Telephone medical discussion with physician, 21-30 minutes | 201 | $41,597 | $118 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $39,747 | $108 |
| New patient visit (60+ min) | 101 | $16,470 | $163 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,814 | $155 |
| Long return visit (40+ min) | 15 | $2,490 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,401 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,669 | $119 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,281 | $107 |
2022: 7 services
| Long return visit (40+ min) | 590 | $228,195 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $21,110 | $93 |
| Telephone medical discussion with physician, 21-30 minutes | 109 | $18,761 | $113 |
| New patient visit (60+ min) | 104 | $16,362 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,892 | $181 |
| Long return visit (40+ min) | 14 | $3,492 | $145 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,473 | $98 |
2021: 8 services
| Long return visit (40+ min) | 527 | $230,652 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $28,059 | $95 |
| Return visit (30+ min) | 219 | $24,672 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 94 | $18,649 | $120 |
| New patient visit (60+ min) | 91 | $15,312 | $168 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $5,482 | $177 |
| Hospital discharge day management, more than 30 minutes | 15 | $2,344 | $94 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | $1,097 | $69 |
2020: 9 services
| Long return visit (40+ min) | 311 | $81,580 | $96 |
| Return visit (30+ min) | 443 | $72,126 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $31,563 | $94 |
| Telephone medical discussion with physician, 21-30 minutes | 86 | $14,913 | $106 |
| New patient visit (60+ min) | 79 | $12,252 | $155 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $10,162 | $181 |
| Short return visit (20+ min) | 107 | $6,410 | $46 |
| Hospital discharge day management, more than 30 minutes | 21 | $3,176 | $93 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $1,152 | $68 |
2019: 10 services
| Long return visit (40+ min) | 358 | $111,722 | $99 |
| Return visit (30+ min) | 464 | $75,344 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 135 | $57,868 | $95 |
| New patient visit (60+ min) | 84 | $12,484 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,874 | $181 |
| Return visit (30+ min) | 40 | $3,044 | $76 |
| Long return visit (40+ min) | 19 | $2,505 | $119 |
| Follow-up observation care per day, typically 35 minutes | 15 | $2,202 | $96 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,394 | $100 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $1,026 | $73 |
2018: 5 services
| Long return visit (40+ min) | 251 | $63,732 | $122 |
| Return visit (30+ min) | 360 | $59,423 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $22,158 | $91 |
| New patient visit (60+ min) | 39 | $7,207 | $185 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,882 | $176 |
2017: 6 services
| Long return visit (40+ min) | 471 | $171,448 | $133 |
| Return visit (30+ min) | 409 | $69,324 | $98 |
| Short return visit (20+ min) | 170 | $21,465 | $67 |
| New patient visit (60+ min) | 94 | $17,588 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $16,452 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,357 | $181 |
2016: 8 services
| Long return visit (40+ min) | 478 | $150,442 | $124 |
| Short return visit (20+ min) | 439 | $105,052 | $63 |
| Return visit (30+ min) | 444 | $70,215 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $21,575 | $89 |
| New patient visit (60+ min) | 105 | $18,562 | $177 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $4,027 | $168 |
| Biopsy of bone marrow | 12 | $1,932 | $161 |
| Aspiration of bone marrow sample for diagnosis | 12 | $953 | $79 |
2015: 12 services
| Return visit (30+ min) | 676 | $164,853 | $97 |
| Short return visit (20+ min) | 313 | $77,981 | $66 |
| Long return visit (40+ min) | 221 | $51,980 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 90 | $35,116 | $90 |
| New patient visit (60+ min) | 127 | $22,883 | $180 |
| Return visit (30+ min) | 306 | $20,592 | $49 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,269 | $173 |
| Short return visit (20+ min) | 100 | $4,987 | $32 |
| New patient visit (60+ min) | 29 | $3,588 | $124 |
| Long return visit (40+ min) | 36 | $3,101 | $84 |
| Biopsy of bone marrow | 16 | $2,589 | $162 |
| Aspiration of bone marrow sample for diagnosis | 17 | $1,436 | $84 |
2014: 10 services
| Return visit (30+ min) | 709 | $155,414 | $65 |
| Short return visit (20+ min) | 393 | $62,830 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 122 | $42,646 | $91 |
| Long return visit (40+ min) | 181 | $29,416 | $93 |
| New patient visit (60+ min) | 203 | $28,556 | $141 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $13,311 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $10,296 | $63 |
| Aspiration of bone marrow sample for diagnosis | 25 | $1,186 | $46 |
| Biopsy of bone marrow | 22 | $1,112 | $51 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 21 | $165 | $8 |
2013: 12 services
| Return visit (30+ min) | 508 | $133,455 | $95 |
| Return visit (30+ min) | 447 | $59,126 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 117 | $34,102 | $88 |
| Short return visit (20+ min) | 235 | $29,625 | $63 |
| Short return visit (20+ min) | 272 | $24,889 | $43 |
| New patient visit (60+ min) | 93 | $16,804 | $181 |
| New patient visit (60+ min) | 85 | $12,078 | $142 |
| Long return visit (40+ min) | 73 | $10,051 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,809 | $172 |
| Long return visit (40+ min) | 46 | $6,808 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $5,412 | $61 |
| Aspiration of bone marrow sample for diagnosis | 13 | $625 | $45 |
Medicaid work
$0 in 2024
Medicaid paid $0 for 16 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 16 | $0 |
| 2024 | 16 | 1 | 13 | $0 |
| 2023 | 20 | 1 | 17 | $46 |
| 2020 | 33 | 1 | 14 | $101 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 20 | $46 |
2020
| Long return visit (40+ min) | 33 | $101 |
Drugs they prescribed that Part D paid
$7,853,370
Pharmacies billed $7,853,370 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (171 of 2,352) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 33% of their opioid prescriptions.
1,558 generic and fewer than 11 brand-name prescriptions · $7,853,370 in drug cost · 55 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Erleada | 62 | $857,084 | $13,824 |
| Xtandi | 59 | $741,892 | $12,574 |
| Brukinsa | 48 | $690,015 | $14,375 |
| Lenalidomide | 50 | $682,431 | $13,649 |
| Imbruvica | 42 | $673,972 | $16,047 |
See all 62 drugs
| Erleada | None | 62 | $857,084 | $13,824 |
| Xtandi | None | 59 | $741,892 | $12,574 |
| Brukinsa | None | 48 | $690,015 | $14,375 |
| Lenalidomide | None | 50 | $682,431 | $13,649 |
| Imbruvica | None | 42 | $673,972 | $16,047 |
| Tagrisso | None | 30 | $508,997 | $16,967 |
| Ibrance | None | 26 | $349,381 | $13,438 |
| Pomalyst | None | 18 | $343,347 | $19,075 |
| Lynparza | None | 32 | $328,511 | $10,266 |
| Verzenio | None | 22 | $322,398 | $14,654 |
| Nubeqa | None | 20 | $271,534 | $13,577 |
| Jakafi | None | 14 | $238,329 | $17,024 |
| Orgovyx | None | 76 | $206,062 | $2,711 |
| Braftovi | None | 11 | $203,685 | $18,517 |
| Cabometyx | None | 17 | $192,418 | $11,319 |
| Sunitinib Malate | None | 16 | $103,824 | $6,489 |
| Eliquis | None | 75 | $85,245 | $1,137 |
| Gamunex-C | Immune globulin | 12 | $54,813 | $4,568 |
| Xarelto | None | 54 | $46,083 | $853 |
| Procrit | None | 11 | $29,221 | $2,656 |
| Erlotinib | None | 21 | $23,398 | $1,114 |
| Abiraterone Acetate | None | 18 | $17,294 | $961 |
| Imatinib Mesylate | None | 25 | $3,493 | $140 |
| Megestrol Acetate | None | 34 | $3,260 | $96 |
| Exemestane | None | 25 | $2,696 | $108 |
| Anastrozole | None | 96 | $2,424 | $25 |
| Hydrocodone-Acetaminophen | None | 56 | $1,206 | $22 |
| Hydroxyurea | None | 41 | $1,181 | $29 |
| Dexamethasone | None | 36 | $1,029 | $29 |
| Pantoprazole | None | 46 | $939 | $20 |
| Hydromorphone | None | 27 | $759 | $28 |
| Fentanyl | None | 11 | $758 | $69 |
| Potassium Chloride | None | 50 | $711 | $14 |
| Bicalutamide | None | 22 | $687 | $31 |
| Gabapentin | None | 70 | $663 | $9 |
| Methadone | None | 34 | $541 | $16 |
| Ondansetron | None | 28 | $514 | $18 |
| Lorazepam | None | 68 | $483 | $7 |
| Prednisone | None | 71 | $443 | $6 |
| Tamoxifen Citrate | None | 15 | $404 | $27 |
| Dutasteride | None | 23 | $403 | $18 |
| Rosuvastatin | None | 41 | $396 | $10 |
| Fluconazole | None | 12 | $361 | $30 |
| Oxycodone | None | 21 | $353 | $17 |
| Alendronate | None | 20 | $345 | $17 |
| Levothyroxine | None | 66 | $295 | $4 |
| Triamcinolone Acetonide | None | 26 | $270 | $10 |
| Temazepam | None | 16 | $196 | $12 |
| Amlodipine Besylate | None | 11 | $189 | $17 |
| Diazepam | None | 17 | $174 | $10 |
| Atorvastatin | None | 21 | $174 | $8 |
| Losartan | None | 24 | $169 | $7 |
| Tamsulosin | None | 21 | $159 | $8 |
| Diphenoxylate-Atropine | None | 11 | $154 | $14 |
| Metformin | None | 16 | $144 | $9 |
| Zolpidem | None | 30 | $126 | $4 |
| Famotidine | None | 13 | $119 | $9 |
| Citalopram Hbr | None | 25 | $102 | $4 |
| Azithromycin | None | 12 | $84 | $7 |
| Ciprofloxacin | None | 13 | $75 | $6 |
| Venlafaxine Hcl Er | None | 23 | $56 | $2 |
| Metoclopramide | None | 11 | $40 | $4 |
Year by year
| 2024 | 2,352 | 366 | 7% (171) | None | $7,853,370 |
| 2023 | 894 | 254 | 4% (34) | None | $1,584,587 |
| 2022 | 600 | 189 | 3% (19) | None | $1,204,804 |
| 2021 | 697 | 184 | 4% (28) | None | $1,304,706 |
| 2020 | 736 | 181 | 5% (39) | 17% | $807,028 |
| 2019 | 826 | 198 | 4% (34) | 22% | $1,159,309 |
| 2018 | 744 | 168 | 5% (34) | 19% | $802,136 |
| 2017 | 1,283 | 231 | 7% (91) | None | $899,304 |
| 2016 | 1,439 | 248 | 6% (81) | None | $647,650 |
| 2015 | 1,709 | 245 | 7% (127) | None | $1,466,770 |
| 2014 | 1,847 | 253 | 12% (228) | None | $1,601,644 |
| 2013 | 2,057 | 234 | 14% (289) | None | $1,235,544 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Erleada | 16 | $231,029 | $14,439 |
| Imbruvica | 14 | $223,428 | $15,959 |
| Tagrisso | 11 | $205,555 | $18,687 |
| Revlimid | 11 | $200,896 | $18,263 |
| Eliquis | 52 | $54,727 | $1,052 |
| Xarelto | 11 | $12,376 | $1,125 |
| Megestrol Acetate | 32 | $3,356 | $105 |
| Anastrozole | 49 | $1,923 | $39 |
| Hydroxyurea | 29 | $1,130 | $39 |
| Dexamethasone | 21 | $916 | $44 |
| Tamoxifen Citrate | 16 | $818 | $51 |
| Potassium Chloride | 23 | $688 | $30 |
| Diphenoxylate-Atropine | 18 | $509 | $28 |
| Pantoprazole | 16 | $342 | $21 |
| Prednisone | 30 | $313 | $10 |
| Hydrocodone-Acetaminophen | 15 | $294 | $20 |
| Lorazepam | 21 | $293 | $14 |
| Rosuvastatin | 21 | $267 | $13 |
| Levothyroxine | 15 | $252 | $17 |
| Venlafaxine Hcl Er | 11 | $236 | $21 |
| Gabapentin | 26 | $228 | $9 |
| Diazepam | 13 | $212 | $16 |
| Ondansetron | 14 | $173 | $12 |
| Zolpidem | 14 | $87 | $6 |
| Atorvastatin | 13 | $78 | $6 |
| Furosemide | 11 | $44 | $4 |
2022: 15 drugs
| Revlimid | 25 | $563,193 | $22,528 |
| Erleada | 16 | $197,376 | $12,336 |
| Imbruvica | 11 | $164,654 | $14,969 |
| Eliquis | 16 | $13,135 | $821 |
| Megestrol Acetate | 19 | $2,261 | $119 |
| Anastrozole | 40 | $1,228 | $31 |
| Bicalutamide | 22 | $959 | $44 |
| Diphenoxylate-Atropine | 14 | $372 | $27 |
| Potassium Chloride | 12 | $343 | $29 |
| Pantoprazole | 14 | $258 | $18 |
| Prednisone | 23 | $217 | $9 |
| Temazepam | 13 | $189 | $15 |
| Citalopram Hbr | 17 | $118 | $7 |
| Gabapentin | 11 | $112 | $10 |
| Lorazepam | 13 | $78 | $6 |
2021: 20 drugs
| Revlimid | 19 | $414,413 | $21,811 |
| Imbruvica | 26 | $328,761 | $12,645 |
| Erleada | 13 | $97,975 | $7,537 |
| Xarelto | 12 | $16,199 | $1,350 |
| Eliquis | 13 | $9,781 | $752 |
| Rosuvastatin | 23 | $1,256 | $55 |
| Anastrozole | 23 | $1,114 | $48 |
| Bicalutamide | 20 | $991 | $50 |
| Dexamethasone | 17 | $649 | $38 |
| Gabapentin | 33 | $616 | $19 |
| Diazepam | 14 | $376 | $27 |
| Potassium Chloride | 14 | $218 | $16 |
| Ondansetron Odt | 14 | $203 | $15 |
| Metoprolol | 11 | $184 | $17 |
| Pantoprazole | 16 | $174 | $11 |
| Prednisone | 21 | $173 | $8 |
| Ciprofloxacin | 15 | $141 | $9 |
| Temazepam | 15 | $118 | $8 |
| Metformin | 14 | $78 | $6 |
| Zolpidem | 17 | $73 | $4 |
2020: 23 drugs
| Inlyta | 14 | $229,547 | $16,396 |
| Imbruvica | 14 | $126,352 | $9,025 |
| Erlotinib | 16 | $66,546 | $4,159 |
| Xarelto | 15 | $20,540 | $1,369 |
| Eliquis | 15 | $11,108 | $741 |
| Megestrol Acetate | 15 | $4,790 | $319 |
| Bicalutamide | 21 | $1,697 | $81 |
| Hydroxyurea | 24 | $1,292 | $54 |
| Anastrozole | 23 | $1,054 | $46 |
| Tamoxifen Citrate | 13 | $742 | $57 |
| Dexamethasone | 16 | $602 | $38 |
| Letrozole | 15 | $432 | $29 |
| Hydrocodone-Acetaminophen | 15 | $402 | $27 |
| Pantoprazole | 16 | $401 | $25 |
| Gabapentin | 28 | $362 | $13 |
| Tamsulosin | 24 | $329 | $14 |
| Levothyroxine | 17 | $274 | $16 |
| Venlafaxine Hcl Er | 13 | $272 | $21 |
| Diazepam | 12 | $271 | $23 |
| Temazepam | 11 | $150 | $14 |
| Prednisone | 23 | $137 | $6 |
| Citalopram Hbr | 13 | $41 | $3 |
| Simvastatin | 15 | $36 | $2 |
2019: 21 drugs
| Revlimid | 34 | $654,238 | $19,242 |
| Imbruvica | 17 | $235,728 | $13,866 |
| Eliquis | 51 | $28,264 | $554 |
| Exemestane | 34 | $13,265 | $390 |
| Enoxaparin | 12 | $4,968 | $414 |
| Anastrozole | 60 | $2,085 | $35 |
| Bicalutamide | 29 | $1,652 | $57 |
| Hydroxyurea | 18 | $1,244 | $69 |
| Letrozole | 12 | $657 | $55 |
| Gabapentin | 24 | $501 | $21 |
| Hydrocodone-Acetaminophen | 19 | $482 | $25 |
| Dexamethasone | 13 | $455 | $35 |
| Tamsulosin | 24 | $448 | $19 |
| Pantoprazole | 31 | $392 | $13 |
| Potassium Chloride | 16 | $355 | $22 |
| Prednisone | 36 | $265 | $7 |
| Lorazepam | 12 | $244 | $20 |
| Triamcinolone Acetonide | 14 | $167 | $12 |
| Levothyroxine | 21 | $116 | $6 |
| Citalopram Hbr | 15 | $63 | $4 |
| Simvastatin | 12 | $55 | $5 |
2018: 23 drugs
| Revlimid | 22 | $367,483 | $16,704 |
| Imbruvica | 16 | $204,362 | $12,773 |
| Eliquis | 32 | $18,946 | $592 |
| Xarelto | 20 | $15,644 | $782 |
| Exemestane | 47 | $14,785 | $315 |
| Enoxaparin | 11 | $5,129 | $466 |
| Anastrozole | 98 | $2,021 | $21 |
| Gabapentin | 22 | $1,200 | $55 |
| Hydroxyurea | 20 | $872 | $44 |
| Bicalutamide | 19 | $782 | $41 |
| Dutasteride | 12 | $569 | $47 |
| Ondansetron | 13 | $454 | $35 |
| Potassium Chloride | 16 | $435 | $27 |
| Pantoprazole | 19 | $300 | $16 |
| Alendronate | 17 | $181 | $11 |
| Tamsulosin | 14 | $178 | $13 |
| Triamcinolone Acetonide | 13 | $129 | $10 |
| Lorazepam | 12 | $123 | $10 |
| Prednisone | 11 | $106 | $10 |
| Losartan | 11 | $101 | $9 |
| Levothyroxine | 18 | $97 | $5 |
| Simvastatin | 11 | $58 | $5 |
| Citalopram Hbr | 13 | $51 | $4 |
2017: 36 drugs
| Imbruvica | 37 | $289,032 | $7,812 |
| Revlimid | 13 | $202,341 | $15,565 |
| Tarceva | 14 | $141,673 | $10,120 |
| Exemestane | 56 | $29,502 | $527 |
| Xarelto | 45 | $26,717 | $594 |
| Eliquis | 26 | $13,100 | $504 |
| Pradaxa | 14 | $5,929 | $424 |
| Anastrozole | 157 | $3,945 | $25 |
| Bicalutamide | 56 | $2,394 | $43 |
| Tamoxifen Citrate | 31 | $1,018 | $33 |
| Hydroxyurea | 23 | $998 | $43 |
| Gabapentin | 18 | $997 | $55 |
| Ondansetron | 24 | $809 | $34 |
| Dutasteride | 13 | $786 | $60 |
| Pantoprazole | 32 | $502 | $16 |
| Potassium Chloride | 20 | $414 | $21 |
| Levothyroxine | 30 | $350 | $12 |
| Letrozole | 12 | $294 | $25 |
| Lorazepam | 45 | $286 | $6 |
| Hydrocodone-Acetaminophen | 17 | $276 | $16 |
| Alendronate | 31 | $264 | $9 |
| Zolpidem | 30 | $259 | $9 |
| Triamcinolone Acetonide | 23 | $246 | $11 |
| Hydromorphone | 12 | $238 | $20 |
| Doxazosin Mesylate | 11 | $211 | $19 |
| Tamsulosin | 14 | $204 | $15 |
| Metformin | 22 | $198 | $9 |
| Citalopram Hbr | 11 | $191 | $17 |
| Diazepam | 12 | $183 | $15 |
| Temazepam | 26 | $179 | $7 |
| Prednisone | 19 | $167 | $9 |
| Alprazolam | 23 | $144 | $6 |
| Promethazine | 11 | $143 | $13 |
| Tramadol | 34 | $121 | $4 |
| Methadone | 11 | $78 | $7 |
| Metoclopramide | 12 | $49 | $4 |
2016: 28 drugs
| Tarceva | 26 | $203,578 | $7,830 |
| Xarelto | 65 | $25,827 | $397 |
| Exemestane | 70 | $25,586 | $366 |
| Pradaxa | 13 | $5,822 | $448 |
| Anastrozole | 174 | $4,027 | $23 |
| Bicalutamide | 61 | $1,734 | $28 |
| Tamoxifen Citrate | 51 | $1,589 | $31 |
| Megestrol Acetate | 18 | $1,560 | $87 |
| Hydroxyurea | 24 | $993 | $41 |
| Hydrocodone-Acetaminophen | 25 | $955 | $38 |
| Pantoprazole | 50 | $910 | $18 |
| Lorazepam | 63 | $782 | $12 |
| Gabapentin | 20 | $769 | $38 |
| Ondansetron | 20 | $618 | $31 |
| Potassium Chloride | 31 | $491 | $16 |
| Letrozole | 24 | $440 | $18 |
| Temazepam | 28 | $338 | $12 |
| Diazepam | 13 | $333 | $26 |
| Dexamethasone | 18 | $331 | $18 |
| Metformin | 32 | $326 | $10 |
| Alendronate | 53 | $272 | $5 |
| Zolpidem | 23 | $266 | $12 |
| Tamsulosin | 21 | $256 | $12 |
| Metoclopramide | 24 | $250 | $10 |
| Omeprazole | 17 | $130 | $8 |
| Tramadol | 28 | $112 | $4 |
| Hydrochlorothiazide | 20 | $62 | $3 |
| Lisinopril | 12 | $45 | $4 |
2015: 49 drugs
| Tarceva | 54 | $405,975 | $7,518 |
| Afinitor | 25 | $264,187 | $10,567 |
| Ibrance | 12 | $118,657 | $9,888 |
| Xtandi | 13 | $115,409 | $8,878 |
| Zytiga | 19 | $93,218 | $4,906 |
| Gleevec | 12 | $54,627 | $4,552 |
| Exemestane | 74 | $24,926 | $337 |
| Xarelto | 59 | $22,486 | $381 |
| Oxycontin | 27 | $13,299 | $493 |
| Arimidex | 11 | $7,145 | $650 |
| Pradaxa | 13 | $6,979 | $537 |
| Leukeran | 12 | $5,915 | $493 |
| Symbicort | 12 | $3,316 | $276 |
| Anastrozole | 170 | $3,093 | $18 |
| Bicalutamide | 59 | $1,981 | $34 |
| Diphenoxylate-Atropine | 21 | $1,304 | $62 |
| Tamoxifen Citrate | 30 | $1,136 | $38 |
| Hydroxyurea | 19 | $825 | $43 |
| Potassium Chloride | 58 | $798 | $14 |
| Gabapentin | 17 | $797 | $47 |
| Hydrocodone-Acetaminophen | 17 | $631 | $37 |
| Hydromorphone | 12 | $604 | $50 |
| Oxycodone | 20 | $585 | $29 |
| Pantoprazole | 37 | $566 | $15 |
| Diazepam | 33 | $558 | $17 |
| Megestrol Acetate | 12 | $549 | $46 |
| Lorazepam | 55 | $506 | $9 |
| Ondansetron | 13 | $454 | $35 |
| Zolpidem | 31 | $452 | $15 |
| Tramadol | 28 | $379 | $14 |
| Nadolol | 11 | $350 | $32 |
| Dexamethasone | 33 | $342 | $10 |
| Triamcinolone Acetonide | 14 | $326 | $23 |
| Prednisone | 31 | $313 | $10 |
| Metformin | 23 | $292 | $13 |
| Levofloxacin | 16 | $286 | $18 |
| Alendronate | 39 | $264 | $7 |
| Metoclopramide | 24 | $250 | $10 |
| Azithromycin | 19 | $239 | $13 |
| Omeprazole | 26 | $237 | $9 |
| Letrozole | 24 | $235 | $10 |
| Methadone | 11 | $189 | $17 |
| Tamsulosin | 13 | $179 | $14 |
| Levothyroxine | 13 | $162 | $12 |
| Amlodipine Besylate | 11 | $93 | $8 |
| Hydrochlorothiazide | 23 | $87 | $4 |
| Temazepam | 12 | $87 | $7 |
| Ciprofloxacin | 14 | $86 | $6 |
| Furosemide | 20 | $46 | $2 |
2014: 55 drugs
| Tarceva | 49 | $334,737 | $6,831 |
| Afinitor | 32 | $304,599 | $9,519 |
| Revlimid | 18 | $214,773 | $11,932 |
| Inlyta | 19 | $198,242 | $10,434 |
| Xtandi | 22 | $181,677 | $8,258 |
| Gleevec | 14 | $67,296 | $4,807 |
| Oxycontin | 27 | $20,466 | $758 |
| Xarelto | 63 | $19,542 | $310 |
| Exemestane | 55 | $18,113 | $329 |
| Anastrozole | 176 | $5,763 | $33 |
| Lyrica | 13 | $4,899 | $377 |
| Celebrex | 12 | $3,371 | $281 |
| Combivent Respimat | 11 | $3,000 | $273 |
| Hydrocodone-Acetaminophen | 70 | $2,334 | $33 |
| Lexapro | 11 | $2,100 | $191 |
| Potassium Chloride | 47 | $1,832 | $39 |
| Tamoxifen Citrate | 41 | $1,152 | $28 |
| Oxycodone | 32 | $1,095 | $34 |
| Gabapentin | 44 | $1,049 | $24 |
| Hydroxyurea | 16 | $741 | $46 |
| Pantoprazole | 27 | $705 | $26 |
| Valsartan-Hydrochlorothiazide | 12 | $652 | $54 |
| Bicalutamide | 28 | $578 | $21 |
| Hydromorphone | 22 | $548 | $25 |
| Lorazepam | 55 | $528 | $10 |
| Valacyclovir | 14 | $473 | $34 |
| Oxycodone-Acetaminophen | 16 | $465 | $29 |
| Diazepam | 32 | $438 | $14 |
| Prednisone | 41 | $383 | $9 |
| Venlafaxine Hcl Er | 20 | $371 | $19 |
| Ondansetron | 16 | $351 | $22 |
| Alendronate | 34 | $328 | $10 |
| Tramadol | 24 | $281 | $12 |
| Metformin | 20 | $266 | $13 |
| Zolpidem | 42 | $266 | $6 |
| Dexamethasone | 32 | $265 | $8 |
| Amox Tr-Potassium Clavulanate | 18 | $262 | $15 |
| Diphenoxylate-Atropine | 12 | $244 | $20 |
| Omeprazole | 15 | $230 | $15 |
| Levofloxacin | 18 | $223 | $12 |
| Ciprofloxacin | 30 | $191 | $6 |
| Mirtazapine | 18 | $189 | $10 |
| Azithromycin | 23 | $183 | $8 |
| Temazepam | 30 | $180 | $6 |
| Amitriptyline | 12 | $165 | $14 |
| Furosemide | 28 | $149 | $5 |
| Letrozole | 13 | $148 | $11 |
| Hydrochlorothiazide | 13 | $111 | $9 |
| Amlodipine Besylate | 19 | $107 | $6 |
| Propranolol | 13 | $103 | $8 |
| Paroxetine | 11 | $92 | $8 |
| Methadone | 17 | $87 | $5 |
| Citalopram Hbr | 11 | $72 | $7 |
| Doxepin | 11 | $69 | $6 |
| Atenolol | 12 | $44 | $4 |
2013: 51 drugs
| Tarceva | 41 | $210,491 | $5,134 |
| Xtandi | 25 | $158,836 | $6,353 |
| Revlimid | 13 | $157,188 | $12,091 |
| Afinitor | 15 | $113,215 | $7,548 |
| Enoxaparin | 24 | $55,814 | $2,326 |
| Erivedge | 11 | $47,354 | $4,305 |
| Oxycontin | 52 | $31,734 | $610 |
| Xarelto | 43 | $11,294 | $263 |
| Exemestane | 35 | $10,583 | $302 |
| Anastrozole | 177 | $7,311 | $41 |
| Pradaxa | 18 | $4,697 | $261 |
| Travasol | 18 | $4,693 | $261 |
| Lyrica | 11 | $3,807 | $346 |
| Dronabinol | 11 | $2,785 | $253 |
| Oxycodone | 51 | $2,540 | $50 |
| Hydromorphone | 42 | $1,961 | $47 |
| Potassium Chloride | 45 | $1,853 | $41 |
| Hydrocodone-Acetaminophen | 75 | $1,630 | $22 |
| Intralipid | 21 | $1,572 | $75 |
| Valsartan-Hydrochlorothiazide | 18 | $1,455 | $81 |
| Gabapentin | 36 | $1,331 | $37 |
| Fentanyl | 14 | $1,320 | $94 |
| Lorazepam | 100 | $756 | $8 |
| Pantoprazole | 38 | $752 | $20 |
| Ondansetron | 36 | $715 | $20 |
| Bicalutamide | 13 | $693 | $53 |
| Tamoxifen Citrate | 39 | $645 | $17 |
| Hydroxyurea | 13 | $585 | $45 |
| Lidocaine-Prilocaine | 16 | $558 | $35 |
| Omeprazole | 16 | $552 | $34 |
| Escitalopram | 14 | $495 | $35 |
| Diazepam | 40 | $424 | $11 |
| Alendronate | 33 | $378 | $11 |
| Zolpidem | 51 | $369 | $7 |
| Metformin | 22 | $349 | $16 |
| Letrozole | 13 | $339 | $26 |
| Azithromycin | 27 | $288 | $11 |
| Dexamethasone | 43 | $267 | $6 |
| Amlodipine Besylate | 18 | $244 | $14 |
| Oxycodone-Acetaminophen | 16 | $243 | $15 |
| Mirtazapine | 20 | $232 | $12 |
| Venlafaxine Hcl Er | 22 | $231 | $10 |
| Temazepam | 16 | $203 | $13 |
| Furosemide | 31 | $187 | $6 |
| Levofloxacin | 15 | $169 | $11 |
| Prednisone | 32 | $167 | $5 |
| Levothyroxine | 15 | $141 | $9 |
| Warfarin | 17 | $135 | $8 |
| Ciprofloxacin | 21 | $122 | $6 |
| Hydrochlorothiazide | 11 | $115 | $10 |
| Atenolol | 13 | $75 | $6 |
Money from drug and device companies
$1,395 in 2025
| 2025 | 4 | 7 | $1,000 | $1,395 |
| 2024 | 1 | 1 | None | $145 |
| 2023 | 2 | 2 | None | $41 |
| 2022 | 1 | 2 | None | $34 |
| 2021 | 1 | 1 | None | $12 |
| 2020 | 12 | 14 | None | $293 |
| 2019 | 18 | 63 | None | $1,224 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Caris MPI | Mi Cancer Seek | $1,233 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $106 | 1 payment
|
| Pfizer | Ibrance | $31 | 1 payment
|
| Daiichi Sankyo | Enhertu | $26 | 1 payment
|
See all 7 published payments
| Caris MPI | Meals · 2025-08-13 | Mi Cancer Seek | $106 |
| Pfizer | Education · 2025-07-10 | Ibrance | $31 |
| Caris MPI | Meals · 2025-06-13 | Mi Cancer Seek | $123 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Lynparza | $106 |
| Caris MPI | Consulting · 2025-05-20 | None | $1,000 |
| Caris MPI | Meals · 2025-05-14 | Mi Cancer Seek | $5 |
| Daiichi Sankyo | Meals · 2025-02-14 | Enhertu | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $145
| ADC Therapeutics America | None | $145 | 1 payment
|
2023: $41
| Pfizer | Ibrance | $25 | 1 payment
|
| Lilly USA | Verzenio | $16 | 1 payment
|
2022: $34
| Novartis Pharmaceuticals | None | $34 | 2 payments
|
2021: $12
| Gilead Sciences | None | $12 | 1 payment
|
2020: $293
| Lilly USA | Alimta | $46 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $36 | 2 payments
|
| Eisai | Lenvima | $27 | 1 payment
|
| Blueprint Medicines | Ayvakit | $25 | 1 payment
|
| Seagen | Padcev | $25 | 1 payment
|
| Incyte | Jakafi | $23 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Novartis Pharmaceuticals | Tasigna | $20 | 1 payment
|
| Puma Biotechnology | Nerlynx | $17 | 1 payment
|
| Celgene | Revlimid | $17 | 1 payment
|
| Foundation Medicine | Foundationone | $16 | 1 payment
|
2019: $1,224
| Lilly USA | Alimta | $151 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $143 | 8 payments
|
| Novartis Pharmaceuticals | Votrient | $139 | 7 payments
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $108 | 6 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $107 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $74 | 4 payments
|
| Pfizer | Ibrance | $70 | 4 payments
|
| Janssen Biotech | Erleada | $54 | 2 payments
|
| Amgen | Nplate | $53 | 2 payments
|
| Incyte | Jakafi | $52 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $51 | 2 payments
|
| Celgene | Revlimid | $49 | 3 payments
|
| EMD Serono | Bavencio | $46 | 3 payments
|
| Seattle Genetics | Adcetris | $42 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $38 | 2 payments
|
| Tesaro | Zejula | $23 | 1 payment
|
| Foundation Medicine | Foundationone | $13 | 1 payment
|
| Clovis Oncology | Rubraca | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · Expanded Access Use of Imdelltra in A 91-Year-Old Patient Who Was Diagnosed With Dll3+ Mixed Adenocarcinoma and High Grade Neuroendocrine Small Cell Carcinoma of the Prostate · 2025 | Their institution | $183,315 |
| Amgen Inc. · Amg 160 Combo in Prostate Cancer 20180101 · 2024 | Their institution | $41,499 |
| Amgen Inc. · Amg 160 Combo in Prostate Cancer 20180101 · 2021 | Their institution | $7,604 |
| Amgen Inc. · Amg 160 Combo in Prostate Cancer 20180101 · 2022 | Their institution | $6,530 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417024654
- Licence
- CA A87232California A87232: Current · expires 2027-10-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A872320
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 2505 Hospital Dr, Mountain View, CA, 94040
- NPI first listed
- 2006-11-30
- NPI last updated
- 2026-04-10
- NPI record certified
- 2026-04-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2505 Hospital Dr, Mountain View, CA, 94040